 Brian Koss
Concepts (153)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Experimental | 2 | 2020 | 111 | 0.750 |
Why?
| | Small Molecule Libraries | 3 | 2019 | 66 | 0.710 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 62 | 0.650 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 86 | 0.640 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 12 | 0.580 |
Why?
| | Biomimetic Materials | 1 | 2016 | 10 | 0.490 |
Why?
| | Proto-Oncogene Proteins | 1 | 2016 | 146 | 0.470 |
Why?
| | Histones | 3 | 2024 | 315 | 0.460 |
Why?
| | Peptide Fragments | 1 | 2016 | 214 | 0.460 |
Why?
| | Melanoma | 3 | 2023 | 272 | 0.430 |
Why?
| | Cell Lineage | 2 | 2014 | 92 | 0.420 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2013 | 20 | 0.410 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 90 | 0.380 |
Why?
| | Mice | 13 | 2023 | 5899 | 0.360 |
Why?
| | Apoptosis | 8 | 2023 | 1120 | 0.320 |
Why?
| | Cell Line, Tumor | 6 | 2020 | 1429 | 0.320 |
Why?
| | Neoplasms | 4 | 2024 | 1314 | 0.300 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 4 | 2014 | 125 | 0.290 |
Why?
| | Animals | 14 | 2024 | 13485 | 0.280 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 1216 | 0.270 |
Why?
| | Ubiquitination | 2 | 2024 | 57 | 0.230 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 257 | 0.220 |
Why?
| | Antigen Presentation | 1 | 2023 | 25 | 0.210 |
Why?
| | Gene Rearrangement | 1 | 2024 | 76 | 0.200 |
Why?
| | Chromatin | 1 | 2024 | 143 | 0.200 |
Why?
| | Mice, Transgenic | 2 | 2016 | 566 | 0.200 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2023 | 21 | 0.200 |
Why?
| | Cell Survival | 5 | 2019 | 598 | 0.190 |
Why?
| | Mice, Inbred C57BL | 4 | 2016 | 1888 | 0.190 |
Why?
| | DNA Damage | 1 | 2024 | 298 | 0.190 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 202 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 101 | 0.180 |
Why?
| | Disease Progression | 1 | 2024 | 870 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 224 | 0.170 |
Why?
| | Histone Code | 2 | 2020 | 32 | 0.170 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 396 | 0.160 |
Why?
| | Transcription Factors | 2 | 2023 | 570 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2019 | 218 | 0.150 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2019 | 47 | 0.150 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 441 | 0.150 |
Why?
| | Integrin alpha Chains | 1 | 2019 | 9 | 0.150 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 32 | 0.150 |
Why?
| | Melanoma, Experimental | 1 | 2019 | 34 | 0.150 |
Why?
| | Cadherins | 1 | 2019 | 61 | 0.150 |
Why?
| | Humans | 17 | 2024 | 52441 | 0.140 |
Why?
| | Antigens, CD | 1 | 2019 | 213 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2017 | 32 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 46 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 423 | 0.130 |
Why?
| | Transfection | 1 | 2016 | 365 | 0.120 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2014 | 1 | 0.110 |
Why?
| | Granulocytes | 1 | 2014 | 27 | 0.110 |
Why?
| | Protein Processing, Post-Translational | 2 | 2020 | 152 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2014 | 42 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 336 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2023 | 140 | 0.110 |
Why?
| | Monocytes | 1 | 2014 | 124 | 0.110 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2013 | 31 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 475 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2013 | 1583 | 0.100 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 39 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2019 | 643 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2013 | 178 | 0.090 |
Why?
| | Mitochondria | 2 | 2013 | 420 | 0.090 |
Why?
| | Peptides | 1 | 2012 | 239 | 0.090 |
Why?
| | Ubiquitin | 1 | 2010 | 70 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2013 | 1483 | 0.070 |
Why?
| | T-Lymphocytes | 2 | 2023 | 318 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2024 | 853 | 0.070 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2024 | 132 | 0.070 |
Why?
| | Structure-Activity Relationship | 2 | 2019 | 399 | 0.060 |
Why?
| | Multiple Myeloma | 1 | 2019 | 3013 | 0.060 |
Why?
| | Camptothecin | 1 | 2024 | 14 | 0.050 |
Why?
| | BRCA1 Protein | 1 | 2024 | 35 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.050 |
Why?
| | Proto-Oncogenes | 1 | 2024 | 27 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2019 | 1013 | 0.050 |
Why?
| | Major Histocompatibility Complex | 1 | 2023 | 13 | 0.050 |
Why?
| | Interferons | 1 | 2023 | 38 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2024 | 236 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2023 | 47 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2024 | 33 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2024 | 187 | 0.050 |
Why?
| | HLA Antigens | 1 | 2023 | 55 | 0.050 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2024 | 202 | 0.050 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 168 | 0.050 |
Why?
| | DNA Repair | 1 | 2024 | 194 | 0.050 |
Why?
| | Cell Respiration | 2 | 2013 | 42 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 145 | 0.050 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2013 | 68 | 0.050 |
Why?
| | Phosphorylation | 1 | 2024 | 536 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 231 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 165 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2023 | 156 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 332 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2023 | 465 | 0.040 |
Why?
| | DNA | 1 | 2023 | 544 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 51 | 0.040 |
Why?
| | Azepines | 1 | 2019 | 21 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 124 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2024 | 805 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 91 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 44 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 178 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 158 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 141 | 0.040 |
Why?
| | Protein Structure, Tertiary | 1 | 2019 | 260 | 0.040 |
Why?
| | Binding Sites | 1 | 2019 | 379 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2016 | 43 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2016 | 59 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 56 | 0.030 |
Why?
| | bcl-X Protein | 1 | 2016 | 53 | 0.030 |
Why?
| | Drug Design | 1 | 2016 | 122 | 0.030 |
Why?
| | Drug Discovery | 1 | 2016 | 94 | 0.030 |
Why?
| | Proteome | 1 | 2017 | 175 | 0.030 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2014 | 4 | 0.030 |
Why?
| | Caspase 8 | 1 | 2014 | 9 | 0.030 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2014 | 19 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 86 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2014 | 142 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2014 | 91 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 217 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 36 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2013 | 69 | 0.030 |
Why?
| | bcl-2-Associated X Protein | 1 | 2013 | 58 | 0.020 |
Why?
| | bcl-2 Homologous Antagonist-Killer Protein | 1 | 2013 | 21 | 0.020 |
Why?
| | Proton-Translocating ATPases | 1 | 2012 | 10 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2013 | 193 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2012 | 113 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 903 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2014 | 667 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 356 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2012 | 234 | 0.020 |
Why?
| | Hematopoietic System | 1 | 2010 | 3 | 0.020 |
Why?
| | Child | 1 | 2023 | 7194 | 0.020 |
Why?
| | Leupeptins | 1 | 2010 | 8 | 0.020 |
Why?
| | Cycloheximide | 1 | 2010 | 34 | 0.020 |
Why?
| | Myocardium | 1 | 2013 | 471 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 37 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2010 | 73 | 0.020 |
Why?
| | Half-Life | 1 | 2010 | 86 | 0.020 |
Why?
| | Protein Stability | 1 | 2010 | 45 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2010 | 101 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 279 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 5508 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 1365 | 0.020 |
Why?
| | Fibroblasts | 1 | 2010 | 357 | 0.020 |
Why?
| | Signal Transduction | 1 | 2014 | 1724 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2013 | 799 | 0.020 |
Why?
| | Heart Failure | 1 | 2013 | 527 | 0.020 |
Why?
| | Cell Line | 1 | 2010 | 1020 | 0.020 |
Why?
| | Mutation | 1 | 2010 | 1331 | 0.010 |
Why?
| | Female | 1 | 2019 | 28277 | 0.010 |
Why?
|
|
Koss's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|